International Journal of Pancreatology

, Volume 24, Issue 3, pp 211–218 | Cite as

The effect of intermittent injections of CCK-8S and the CCK-A receptor antagonist devazepide on cell proliferation in exocrine rat pancreas

  • Bodil Ohlsson
  • Karin Borg
  • Jens F. Rehfeld
  • Ingemar Ihse
  • Jan Axelson
Original Articles



Intermittent injections of sulfated cholecystokinin-8 (CCK-8S) or devazepide caused longlasting effects on cell proliferation in exocrine pancreas in contrast to continuous infusion. The acinar cells responded to both treatments with changes in the labeling index (LI) during the whole study period. When studying the influence of stimulation and inhibition of the CCK-A receptor on cell proliferation in the exocrine pancreas, not only are the drugs and doses of importance but also the mode of administration.


Continuous infusion of CCK-8S or the CCK-A receptor antagonist devazepide induces transient changes in acinar cell proliferation in rat pancreas. The aim of the present experiments was to study whether intermittent administration of CCK-8S or devazepide prevents receptor desensitization and thereby affects exocrine pancreatic cell proliferation persistently.


Male Sprague-Dawley rats were injected subcutaneously twice daily with CCK-8S (6 μg), devazepide (240 μg) or bovine serum albumin (BSA). The rats were sacrificed after 18 and 36 h and 3 and 7 d. One hour before sacrifice, the rats were injected intraperitoneally with 1 mCi/kg of tritiated thymidine. The pancreatic weight and the contents of water, protein, and DNA were determined. The LI (number of labeled cells/100 cells) of exocrine pancreatic cells was determined microscopically after autoradiography.


The concentration of plasma CCK was slightly increased by devazepide, but the increase was more pronounced by CCK-8S. The pancreatic wet weight was transiently increased 18 h after the start of CCK-8S injections (+14%), whereas devazepide caused a reduction after 7 d (−22%). The protein content was uninfluenced and the DNA content was decreased at 36 h with either treatment. CCK-8S increased the LI in acinar and centroacinar cells throughout the study period, but the ductal cell LI was increased only after 18 and 36 h. Injection of devazepide was followed by decreased LI of acinar cells throughout the study period. Also, the centroacinar and ductal cell LI decreased initially but returned to control values after 7 d.

Key Words

Cell proliferation cholecystokinin intermittent injections pancreas 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Ohlsson B, Axelson J, Sternby B, Rehfeld JF, Ihse I. Time-course of the pancreatic changes following long-term stimulation or inhibition of the CCK-A receptor.Int J Pancreatol 1995; 18: 59–66.PubMedGoogle Scholar
  2. 2.
    Lütke H, Scheele GA, Kern HF. Time course and cellular site of mitotic activity in the exocrine pancreas of the rat during sustained hormone stimulation.Cell Tissue Res 1987; 247: 385–391.Google Scholar
  3. 3.
    Gasslander T, Axelson J, Håkansson R, Ihse I, Lilja I, Rehfeld JF. Cholecystokinin is responsible for the growth of the pancreas following pancreatico-biliary diversion in rats.Scand J Gastroenterol 1990; 25: 1060–1065.PubMedCrossRefGoogle Scholar
  4. 4.
    Solomon TE, Vanier M, Morriset J. Cell site and time course of DNA synthesis in pancreas after caerulein and secretin.Am J Physiol 1983; 245: G99-G105.PubMedGoogle Scholar
  5. 5.
    Gasslander T, Smeds S, Blomqist L, Ihse I. Proliferative response of different exocrine pancreatic cell types to hormonal stimuli. I: Effects of long term cerulein administration.Scand J Gastroenterol 1990; 25: 1103–1110.PubMedCrossRefGoogle Scholar
  6. 6.
    Rehfeld JF. Immunochemical studies on cholecystokinin.J Biol Chem 1978; 253: 4016–4021.PubMedGoogle Scholar
  7. 7.
    Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the folin phenol reagent.J Biol Chem 1951; 193: 265–275.PubMedGoogle Scholar
  8. 8.
    Bhat ST, Talkad VD, Pollo DA, Gardner JD. Characterization of a persistent inhibitory action of L-364, 718 on cholecystokinin-stimulated enzyme secretion in pancreatic acini.Pancreas 1994; 9: 101–108.PubMedCrossRefGoogle Scholar
  9. 9.
    Zucker KA, Adrian TE, Bilchik AJ, Modlin IM. Effects of the CCK receptor antagonist L 364, 718 on pancreatic growth in adult and developing animals.Am J Physiol 1989; 257: G511-G516.PubMedGoogle Scholar
  10. 10.
    Varga G, Dobronyi I, Papp M. Time specific development of pancreatic hypersecretory capacity during chronic caerulein treatment in rats.Scand J Gastroenterol 1989; 24: 565–570.PubMedCrossRefGoogle Scholar
  11. 11.
    Douglas BR, Woutersen RA, Jansen JBMJ, de Jong AJL, Lamers CBHW. The influence of different nutrients on plasma cholecystokinin levels in rat.Experientia 1988; 44: 21–23.PubMedCrossRefGoogle Scholar
  12. 12.
    Axelson J, Håkanson R, Ihse I, Lilja I, Rehfeld JF, Sundler F. Effects of endogenous and exogenous cholecystokinin and of infusion with the cholecystokinin antagonist L-364, 718 on pancreatic and gastrointestinal growth.Scand J Gastroenterol 1990; 25: 471–480.PubMedCrossRefGoogle Scholar
  13. 13.
    Cantor P, Mortensen PE, Myhre J, Gjorup I, Worning H, Stahl E, Survill TT. The effect of the cholecystokinin receptor antagonist MK-329 on meal-stimulated pancreaticobiliary output in humans.Gastroenterology 1992; 102: 1742–1751.PubMedGoogle Scholar
  14. 14.
    Axelson J, Ihse I, Håkansson R. Pancreatic cancer: the role of cholecystokinin?Scand J Gastroenterol 1992; 27: 993–998.PubMedCrossRefGoogle Scholar
  15. 15.
    Abbruzzese JL, Gholson CF, Daughherty K, Larson E, Dubrow R, Berlin R, Levin B. A pilot clinical trial of the cholecystokinin receptor antagonist MK-329 in patients with advanced pancreatic cancer.Pancreas 1992; 7: 165–171.PubMedCrossRefGoogle Scholar
  16. 16.
    Herrington MK, Permert J, Kazakoff KR, Pour PM, Zucker KA, Bilchik AJ, Adrian TE. Effects of high fat diet and cholecystokinin receptor blockade on pancreatic growth and tumor initiation in the hamster.Carcinogenesis 1993; 14: 1021–1026.PubMedCrossRefGoogle Scholar
  17. 17.
    Herrington MK, Permert J, Kazakoff KR, Zucker KA, Bilchik AJ, Pour PM, Adrian TE. Effects of raw soya diet and cholecystokinin receptor blockade on pancreatic growth and tumor initiation in the hamster.Cancer Lett 1994; 82: 7–16.PubMedCrossRefGoogle Scholar
  18. 18.
    Douglas BR, Woutersen RA, Jansen JBMJ, de Jong AJL, Rovati LC, Lamers CBHW. Influence of cholecystokinin antagonist on the effects of cholecystokinin and bombesin onazaserine-induced lesions in rat pancreas.Gastroenterology 1989; 96: 462–469.PubMedGoogle Scholar
  19. 19.
    Smith JP, Kramer S, Bagheri S. Effect of a high-diet and L 364, 718 on growth of human pancreas cancer.Dig Dis Sci 1990; 35: 726–732.PubMedCrossRefGoogle Scholar
  20. 20.
    Beguinot L, Hanover JA, Ito S, Richtert ND, Willingham MC, Pastan I. Phorbol esters induce transient internalization without degradation of unoccupied epidermal growth factor receptors.Proc Natl Acad Sci USA 1985; 82: 2774–2778.PubMedCrossRefGoogle Scholar
  21. 21.
    Watanapa P, Flaks B, Oztas H, Deprez PH, Calam J, Williamson RCN. Enhancing effect of partial gastrectomy on pancreatic carcinogenesis.Br J Cancer 1992; 65: 383–387.PubMedGoogle Scholar

Copyright information

© Humana Press Inc 1998

Authors and Affiliations

  • Bodil Ohlsson
    • 2
  • Karin Borg
    • 2
  • Jens F. Rehfeld
    • 1
  • Ingemar Ihse
    • 2
  • Jan Axelson
    • 2
  1. 1.Department of Clinical BiochemistryRigshospitaletCopenhagenDenmark
  2. 2.Department of SurgeryUniversity HospitalLundSweden

Personalised recommendations